Filtered By:
Condition: Pregnancy
Therapy: Chemotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 15 results found since Jan 2013.
A Serious Diagnosis Lacking Common Symptoms
BY JENNIFER TUONG; IVAN KHARCHENKO; JEAN LUC AGARD; & AHMED RAZIUDDIN, MDA 65-year-old man who had HIV well-controlled with highly active antiretroviral therapy, hypertension, sciatica, and restless leg syndrome presented to the emergency department with left leg pain. He also had had chemotherapy and radiation for anal cancer. The patient said the pain had started 45 minutes earlier when he was sitting on the toilet.He described the pain as sore in quality and 10/10 on the pain scale. He reported that it had started in his lower back and radiated to his left leg. He said he had had no trauma or weakness to the regi...
Source: The Case Files - May 28, 2019 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Stem Cells for Cell-Based Therapies
The world of stem cells
We know the human body comprises many cell types (e.g., blood cells, skin cells, cervical cells), but we often forget to appreciate that all of these different cell types arose from a single cell—the fertilized egg. A host of sequential, awe-inspiring events occur between the fertilization of an egg and the formation of a new individual:
Embryonic stem (ES) cells are also called totipotent cells.
The first steps involve making more cells by simple cell division: one cell becomes two cells; two cells become four cells, etc.
Each cell of early development is undifferentiated; that is, it is...
Source: ActionBioscience - December 28, 2012 Category: Science Authors: Ali Hochberg Source Type: news
Primary Ovarian Insufficiency
Abstract
Primary ovarian insufficiency (POI) is a syndrome of amenorrhoea, sex steroid deficiency, and elevated gonadotropins in a woman aged more than two standard deviations below the mean age for menopause estimated for her reference population. In practical terms, it occurs spontaneously in 1 % of women before the age of 40 years. Apart from idiopathic POI, many women will have impaired ovarian function by age 40 years as a consequence of surgery, chemotherapy, or radiotherapy. Of identifiable causes of POI, the most common are concurrent autoimmune diseases such as thyroid and adrenal disease, and chromoso...
Source: Current Obstetrics and Gynecology Reports - September 3, 2014 Category: OBGYN Source Type: research
Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation
CONCLUSIONS
The available evidence on the risks of thrombosis for women undergoing ovarian stimulation for fertility preservation due to a malignancy is reassuring. However the avoidance of the early form of OHSS in women preserving oocytes/embryos due to malignancy is crucial. For these cycles, we advocate the use of a regimen of ovarian stimulation with gonadotrophin releasing hormone (GnRH) antagonists using GnRH agonists to trigger ovulation, an approach that has been shown to markedly reduce the risk of OHSS. Antithrombotic prophylaxis should be administered only to selected subgroups of women such as those with other...
Source: Human Reproduction Update - October 14, 2014 Category: OBGYN Authors: Somigliana, E., Peccatori, F. A., Filippi, F., Martinelli, F., Raspagliesi, F., Martinelli, I. Tags: Reviews Source Type: research
Fatal Folic Acid Toxicity in Humans.
Abstract
Folic acid is B-9 vitamin. Folic acid is prescribed commonly for pregnant women to prevent neural tube defects in the fetus, patients under chemotherapy, pernicious anemia and to reduce the risk of stroke and cardiovascular disease. Acute or chronic ingestion of a large dose of folic acid generally manifests as neurological complications, which are reversible. In this present case, a 23-year-old pregnant woman committed suicide by consuming folic acid tablets and succumbed to death within 36 h. Postmortem toxicological analysis detected folic acid in viscera. Death following acute consumption of folic aci...
Source: Journal of Forensic Sciences - March 5, 2017 Category: Forensic Medicine Authors: Devnath GP, Kumaran S, Rajiv R, Shaha KK, Nagaraj A Tags: J Forensic Sci Source Type: research
Fatal folic acid toxicity in humans - Devnath GP, Kumaran S, Rajiv R, Shaha KK, Nagaraj A.
Folic acid is B-9 vitamin. Folic acid is prescribed commonly for pregnant women to prevent neural tube defects in the fetus, patients under chemotherapy, pernicious anemia and to reduce the risk of stroke and cardiovascular disease. Acute or chronic ingest...
Source: SafetyLit - March 11, 2017 Category: Global & Universal Tags: Home and Consumer Product Safety Source Type: news
Nivolumab-induced posterior reversible encephalopathy syndrome
A 47-year-old woman with metastatic, poorly differentiated lung cancer with neuroendocrine features was brought to the hospital after 4 days of nausea, vomiting, disorientation, and 1 generalized tonic clonic seizure. On examination, her blood pressure was 148/95 mm Hg, heart rate 95 bpm, and temperature 36.4°C. She was encephalopathic and had cortical blindness. She had no history of seizures or visual impairment. MRI brain without contrast showed changes consistent with posterior reversible encephalopathy syndrome (PRES; figure, A). She had been on nivolumab, of which she had received 2 doses; the last dose was 24 da...
Source: Neurology Clinical Practice - October 16, 2017 Category: Neurology Authors: Hussein, H. M., Dornfeld, B., Schneider, D. J. Tags: MRI, Other cerebrovascular disease/ Stroke, All Clinical Neurology, Chemotherapy-tumor Case Source Type: research
Goal-directed therapy with bolus albumin 5% is not superior to bolus ringer acetate in maintaining systemic and mesenteric oxygen delivery in major upper abdominal surgery: A randomised controlled trial
CONCLUSION
Bolus human albumin 5% was not superior to bolus ringer acetate in maintaining systemic or mesenteric oxygen delivery in elective major upper gastrointestinal cancer surgery, despite the administration of larger volumes of trial fluid in the ringer acetate group. No significant difference was seen in fluid-related complications or LOS.
TRIAL REGISTRATION
https://eudract.ema.europa.eu/ Identifier: 2013-002217-36.
Source: European Journal of Anaesthesiology - May 11, 2020 Category: Anesthesiology Tags: Haemodynamics Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments.
As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective.
That turned out to be acupuncture.
“Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
